News

Biocon registers Rs 3,516 crore revenues in Q1, up 59% YoY Indian pharmaceuticals giant Biocon registered Rs 3,516 crore revenues for Quarter 1 of FY 2024. An official statement issued by the company on Thursday said that the profits were up by 59 per cent year-on-year. The revenues of biosimilars are up by 106 per cent while that of research services are up by 25 per cent, the statement said.    "We have had a strong start to the year. At a consolidated level, revenues rose 59 per cent YoY to Rs 3,516 crore driven primarily by t...
Biocon registers Rs 3,516 crore revenues in Q1, up 59% YoY
Biocon registers Rs 3,516 crore revenues in Q1, up 59% YoY
Source: IANS
11/08/2023 10:10:47 AM
Kiran Mazumdar-Shaw retires from Infosys Board, D. Sundaram appointed Lead Independent Director Indian IT major Infosys has announced the retirement of Kiran Mazumdar-Shaw as Independent Director of the Board, effective March 22, 2023, upon completion of her tenure. The Board has appointed D. Sundaram as the Lead Independent Director of Company, effective March 23, 2023 based on the recommendation of Nomination and Remuneration Committee. Kiran Mazumdar-Shaw was appointed to the Infosys Board as an Independent Director in 2014, and as Lead Independent Director in 2018. She also se...
Kiran Mazumdar-Shaw retires from Infosys Board, D. Sundaram appointed Lead Independent Director
Kiran Mazumdar-Shaw retires from Infosys Board, D. Sundaram appointed Lead Independent Director
Source: IANS
23/03/2023 3:05:19 PM
Biocon Q3FY23 revenue at Rs 3,020 crore, up 36% Global biopharmaceuticals company Biocon Ltd on Tuesday announced its net revenue from operations for the quarter, ending December 31, 2022. increased by 36 per cent to Rs 3,020 crore from Rs 2,223 crore in the same period last year. Executive Chairperson, Biocon and Biocon Biologics Kiran Mazumdar-Shaw said: "Q3 FY23 has been an eventful quarter which saw the completion of the global acquisition of our partnered Biosimilars business from Viatris on Nov 29, 2022. "We are now i...
Biocon Q3FY23 revenue at Rs 3,020 crore, up 36%
Biocon Q3FY23 revenue at Rs 3,020 crore, up 36%
Source: IANS
15/02/2023 10:54:09 AM
Vikram Kirloskar, Toyota Kirloskar vice-chairman, passes away Vikram Shreekant Kirloskar, an eminent industrialist and Vice-Chairman of Toyota Kirloskar Motors passed away after suffering a cardiac arrest late Tuesday. He was 64. His funeral is scheduled for 1 p.m. on Wednesday in Bengaluru, according to family sources. Toyota India tweeted, "We are extremely saddened. At this time of grief, we request everyone to pray that his soul rests in peace." Karnataka Chief Minister Basavaraj Bommai condoled the death. "Heartfelt condolen...
Vikram Kirloskar, Toyota Kirloskar vice-chairman, passes away
Vikram Kirloskar, Toyota Kirloskar vice-chairman, passes away
Source: IANS
30/11/2022 12:50:34 PM
Biocon Biologics completes acquisition of Viatris Inc Biocon Biologics Ltd, a subsidiary of listed biopharmaceutical company Biocon Ltd, on Tuesday announced the completion of its acquisition of global biosimilars business of its partner Nasdaq listed Viatris Inc. Biocon Biologics and Viatris have obtained all applicable approvals from key global regulators, including the US Federal Trade Commission, the Competition Commission of India, the Reserve Bank of India, and its investors, a company statement said. The acquisition provides Biocon ...
Biocon Biologics completes acquisition of Viatris Inc
Biocon Biologics completes acquisition of Viatris Inc
Source: IANS
30/11/2022 9:51:10 AM
SEBI needs to act rationally in insider trading verdicts: Kiran Mazumdar-Shaw A day after the capital market regulator barred brokerage firm Allegro Capital Pvt Ltd and its Chairman from the securities market for one year over insider trading in the shares of Biocon Ltd, the biopharmaceutical major's Executive Chairperson, Kiran Mazumdar-Shaw on Friday said that SEBI should act "rationally" in terms of judgement in matters of alleged insider trading. She questioned the basis for relating the Mazumdar Shaw Medical Foundation to Biocon in the judgement. ...
SEBI needs to act rationally in insider trading verdicts: Kiran Mazumdar-Shaw
SEBI needs to act rationally in insider trading verdicts: Kiran Mazumdar-Shaw
Source: IANS
10/07/2021 10:00:56 AM